Introduction
Tumor resistance to chemotherapeutic drugs is a common problem that limits the efficacy of these drugs in the clinical setting. The mechanisms for how tumors develop resistance to chemotherapeutic drugs are still poorly understood; however, it is generally agreed that alterations in a number of genetic pathways are probably essential for the development of drug resistance. cDNA microarray analysis is a recently developed technique that may assist in the elucidation of genetic pathways important for the development of drug resistance. This powerful technique permits the simultaneous determination of expression patterns for hundreds to thousands of genes at one time. A few recent studies using microarray analysis evaluated the gene expression patterns of drug-naı¨ve cell lines from the National Cancer Institute's drug screening program (NCI-ACDS) panel of 60 human cell lines and correlated the gene expression patterns obtained with the sensitivity of the same cell lines to various chemotherapeutic drugs observed previously (Amundson et al., 2000; Scherf et al., 2000; Dan et al., 2002) . The difficulties with this bioinformatic approach to unraveling the mechanisms of drug resistance development are that these studies involve untreated cells and, therefore, focus more on sensitivity to therapy rather than on the molecular consequences of therapy (Scherf et al., 2000) .
However, identifying the molecular consequences of therapy will more readily assist investigators in determining suitable molecular targets for the prevention or reversal of chemotherapeutic drug resistance. Toward this end, several preclinical studies have identified specific genes that are cisplatin inducible, and have attempted to relate the genes mechanistically to cisplatin resistance. For example, cancer patients resistant to platinum-based therapy had a 2.6-fold higher expression level of the repair endonuclease ERCC1 in their tumor tissue than did patients who responded to therapy (Dabholkar et al., 1992) . Expression of the ERCC1 gene, which is needed for repair of DNA damage induced by cisplatin, was related to the level of cisplatin resistance of tumor cells in vitro (Li et al., 2000) . Mechanistically, ERCC1 may influence cisplatin resistance via effects on apoptosis. Chinese hamster ovary (CHO) mutant fibroblasts defective in ERCC1 showed a higher frequency of apoptosis, due to a decline in Bcl-2 protein level, activation of caspases 8, 9 and 3 and poly(ADP-ribose) polymerase (PARP) cleavage (Dunkern et al., 2001) . The BRCA genes that, when mutated, increase the risk of early onset breast and ovarian cancers, are also cisplatininducible. BRCA1 interacts with the recombinational repair protein Rad51, and participates in homologous recombinational repair pathways (Moynahan et al., 1999) . BRCA1 also participates in a variety of other DNA damage responses, including transcriptioncoupled base excision repair of oxidative DNA damage (Abbott et al., 1999) , and interaction with proteins required for DNA-end joining, nucleotide mismatch repair, DNA replication, and signal transduction in response to damage (Wang et al., 2000) . Bhattacharyya et al. (2000) attempted to determine which of these specific mechanisms is important in the BRCA1 response to cellular damage resulting from cisplatin treatment. They performed clonogenic survival assays in mouse embryonic stem cells to obtain direct evidence implicating BRCA1 in cisplatin resistance, and found that the BRCAÀ/À mutant line was fivefold less resistant to cisplatin than the wild-type cell line. Their results are consistent with the hypothesis that BRCA1 contributes to cisplatin resistance through its effect on Rad51 focus formation. They concluded that BRCA1 contributes to cisplatin resistance, at least in part, by promoting the assembly of Rad51 at cisplatin-damaged replication forks.
In order to identify meaningful molecular targets, such as BRCA1 and ERCC1, for modulating drug resistance, model systems need to be developed that effectively accomplish this goal. As a means of identifying the molecular consequences of therapy, one group has used a model system composed of a drug-naı¨ve, parental cell line, panc-1 pancreatic cancer cells, and the same cell line that has been made drug resistant after multiple exposures to the same drug (Anderson et al., 2002) . Another group furthered this type of analysis by also exploring the gene expression changes at multiple time points during a transient 15-h exposure of drug-naı¨ve MCF-7 breast cancer cells to doxorubicin (Kudoh et al., 2000) . These two model systems are more appropriate for the evaluation of the molecular consequences of therapy. However, we are not aware of any published cDNA microarray studies involving a time-course comparison between a drug-naı¨ve cell line and the same cell line treated multiple times with the drug of interest. A time-course experimental system should permit optimal evaluation of the molecular consequences of drug therapy. Notwithstanding, a major limitation of such an experimental system, and the previous two model systems discussed using Panc-1 and MCF-7 cells, is that differential expression does not necessarily mean that a gene is directly involved in the development of cisplatin resistance; the differential gene expression may simply be a passive response to cisplatin treatment, independent of the development of drug resistance.
In this study, we report that a novel, time-course cDNA microarray analysis method -designed in such a way to evaluate more thoroughly as to which differentially expressed genes may be directly involved in the drug resistance development process -was able to identify unique genes not previously associated with the development of drug resistance to cisplatin. Interestingly, some of the genes identified have been associated with cancer progression in earlier studies.
Results

MTT-based cytotoxicity assay
The results of the MTT-based cytotoxicity assay to determine the extent of cisplatin resistance in NCI-H226 are depicted in Figure 1a and those for NCI-H2170 are depicted in Figure 1b . The NCI-H226 cell line developed significant resistance to cisplatin throughout the 5-week time-course study. NCI-H2170 was protracted to the development of cisplatin resistance. Cisplatin resistance was induced in the cell line during week 4 due to the higher dose of cisplatin used in the fourth week; however, the resistance was completely reversed by the end of the fifth week. Differentially expressed genes associated with the development of cisplatin resistance Figure 2 shows the distribution of differentially expressed genes in treated squamous cell lung cancer cell lines. In NCI-H226 during the 5-week time-course experiment, 27 genes were overexpressed in at least 1 week and were also underexpressed in at least 1 week. There were 67 (40 þ 27) genes overexpressed in at least 1 week, and 106 (79 þ 27) genes underexpressed in at least 1 week (Figure 2a) . Of the subset of 193 genes that satisfied our exclusion criteria, 47 genes did not change significantly in at least 1 week.
In NCI-H2170, 14 genes were overexpressed in at least 1 week and underexpressed in at least 1 week (Figure 2b ). There were 71 (57 þ 14) genes underexpressed in 1 week, and seven underexpressed in 2 weeks. In addition, of the 49 (35 þ 14) genes overexpressed in the H2170 experiment in at least 1 week, 16 (42.0 %) were overexpressed in week 4. Of the 211 genes, 105 genes did not change during the 5-week time-course experiment.
Of the 24 genes that changed at least twofold from weeks 3 to 4 in NCI-2170 (Table 1) , we identified seven genes ( Tables 2 and 3 ) that, we believe, are likely to be involved in cisplatin resistance from our analysis of the larger subsets described above. Note that A10f (stromelysin3) was also illustrated in Table 3 , even though the change from weeks 3 to 4 was moderate (1.7-fold increase).
The results for interferon-inducible protein 9-27 (IIP 9-27) (coordinate A01h) can serve to illustrate how temporal gene expression changes were evaluated using the microarray and MTT-based assay data for NCI-H2170. Note that during the first 3 weeks, the foldchange values given for IIP 9-27 are at baseline, which indicates that the unadjusted (un-normalized) intensity of the gene for both the cisplatin-treated and control cells was at or near the background level determined for the microarray. During the fourth week, when NCI-H2170 was treated with a larger dose of cisplatin to induce cisplatin resistance (see Figure 1b) , the unadjusted intensity for the control remained at the background level, but that for the cisplatin-treated cells was 4.3-fold above the background. During week 5, when NCI-H2170 was treated with a lower dose of cisplatin compared to the fourth week to reverse the cisplatin resistance observed in the fourth week (see Figure 1b) , the unadjusted intensity for the cisplatin-treated cell line drops to 2.4-fold above the background; the control was at or near the background.
Correlation between PCR and gene expression
The relationship between the gene expression levels and real-time PCR for the genes likely to be involved in cisplatin resistance, except ERBB-3, is shown in Tables  2 and 3 . For the NCI-H226 cell line, there were five genes over-or underexpressed in at least 1 week confirmed by PCR. Similarly, there were four genes over-or underexpressed in at least 1 week confirmed by PCR for the NCI-H2170. Examination of fold change from weeks 3 to 4 for the NCI-H2170 indicated that three genes showed at least a twofold change by PCR. The Pearson correlation between PCR and gene expression among the six genes was 40% (P ¼ 0.017) for the NCI-H226 and 57% (Po0.001) for the NCI-H2170.
Discussion
The goals of this study were to identify novel gene expression alterations that are directly associated with the development of cisplatin resistance. For this reason, a 5-week time-course experiment was chosen to evaluate the relative importance of a gene to cisplatin resistance. The NCI-H226 cell line was initially used to screen for novel gene changes associated with cisplatin resistance (Table 1) . This experiment was then followed by another 5-week time-course experiment using the NCI-H2170 cell line. The significantly protracted ability of NCI-H2170 to develop cisplatin resistance provided an opportunity to distinguish candidate genes that may be directly rather than passively involved in the cisplatin resistance development process. The results of the MTTbased cytotoxicity assays performed during the 5-week time-course experiment with NCI-H2170 demonstrate that the most significant cisplatin resistance was attained at the end of the fourth week of the experiment; however, during the fifth week of the experiment the cisplatin resistance was completely reversed. The reversal of cisplatin resistance in the fifth week suggests that the gene changes observed during the fourth and fifth weeks of the experiment could assist in identifying the genes that perhaps are most important to the development of cisplatin resistance in this model system. We were hopeful that genes initially identified using NCI-H226 would alter their expression patterns in NCI-H2170 during the fourth week of the experiment and that during the fifth week of the experiment, when the cells were treated with a lower dose of cisplatin, the gene expression alterations observed would be reversed coincident with the reversal of cisplatin resistance.
Our findings demonstrate the utility of using the timecourse method to identify genes that may be directly rather than passively involved in the development of cisplatin resistance. To our knowledge, such a timecourse study has never been performed for any chemotherapeutic drug. Temporal changes in gene expression might also prove informative in evaluating the outcome of treatment in a clinical setting, or in following the progress of a treatment to permanent change in gene expression. Evidence of associations between temporal change in gene expression and induction of treatment failure is sparse for patients undergoing chemotherapy, because repeated tissue sampling is not feasible in these patients. A cell culture model evaluated the evolution of paclitaxel resistance in three SKOV-3 sublines that were selected during successive rounds of exposure to increasing paclitaxel concentrations (Lamendola et al., 2003) . A self-organizing map was developed, which was shown to discriminate between genes that were differentially expressed in early, intermediate and late stages of paclitaxel resistance. Various expression patterns were revealed, including early sustained increases and early sustained decreases in gene expression. These results suggest that temporal changes do progress to significant and fixed change. A cDNA microarray analysis of human CWR22 prostate cancer xenografts during androgen deprivation therapy revealed temporal changes in the gene expression profile as a function of therapy response (Mousses et al., 2001) . It was suggested that changes in the expression of genes involved in the transition between primary, regressing and recurrent tumors might point to molecular mechanisms that affect therapy failure and tumor progression. These reports suggest that timecourse analysis of gene expression during cancer therapy may reveal important patterns of change in expression that might be overlooked in pre-and post-treatment models.
This time-course analysis enabled us to narrow the candidate genes associated with the development of cisplatin resistance to a total of seven genes, four of which -interferon-inducible protein 9-27 (IIP 9-27), stromelysin-3 (Str-3), ERBB-3 and macrophage inhibitory cytokine 1 (MIC1) -will be discussed below.
IIP 9-27 is a cell-membrane-bound cytokine that can be induced by interferons, such as interferon-g. IIP 9-27 transduces signals that eventually activate the transcription of the so-called type I interferon genes that promote growth inhibition (Henderson et al., 1997) . No studies have implicated IIP 9-27 in the development of resistance to any chemotherapeutic drug. A possible rationale for the enhanced expression of IIP 9-27 in our model system is provided by Clave et al. (1997) . In this study, a human p53-deficient leukemic cell line, KG1a, was used to evaluate the effect of X-ray treatment of these cells on gene expression. The authors identified various alterations in the expression patterns of genes, including IIP 9-27, previously related to interferon induction. The surprising element of this study was that IIP 9-27 upregulation was apparently not caused by interferon because interferon-g expression was not altered. This finding suggests that IIP 9-27 may not necessarily be stimulated only by interferons but may also be stimulated in response to various cytotoxic insults. The biological significance of IIP 9-27 to cisplatin cytotoxicity and subsequent development of cisplatin resistance should be further evaluated.
Str-3 is a matrix metalloproteinase (MMP) that has proteolytic activity, but does not have any apparent ability to degrade extracellular matrix, which is the case with many of the other MMPs (Boulay et al., 2001 ). This protein is usually expressed only by stromal cells and is also expressed by epithelial cells present in basaloid and squamous carcinomas (Anderson et al., 1995; Bolon et al., 1997) . Str-3, to our knowledge, has never been associated with the development of resistance to any commonly used chemotherapeutic agent. Interestingly, Str-3 has been related to cancer progression; therefore, the development of drug resistance may also be associated with or even encourage the development of a more malignant phenotype. De Larco et al. (2001) have previously shown that cells treated with chemotherapeutic drugs can develop a more malignant phenotype. Str-3 may be a useful prognostic marker predicting enhanced local metastasis to lymph nodes in lung adenocarcinomas and squamous cell carcinomas (Delebecq et al., 2000) . As Str-3 does not have any ability to degrade extracellular matrix components, this MMP must be functioning in another way to enhance tumor invasiveness. Noel et al. (1996) demonstrated that tumor cells subcutaneously inoculated into nude mice were significantly more likely to develop into tumors when the cells were first transfected with the Str-3 gene. The cells did not have a greater rate of proliferation, but apparently were better able to survive after subcutaneous inoculation into an environment not permissive for tumor growth. The increased expression of Str-3 in the present model system suggests that Str-3 may enhance the survival of tumor cells to cytotoxic insults such as cisplatin chemotherapy, while at the same time perhaps promoting cancer progression.
The epidermal growth factor receptor family consists of four known members that are involved in cell proliferation and other cellular processes, including drug resistance; however, it is becoming more appreciated that one specific member of this family, ERBB-3, may be of greater importance in the development of drug resistance. For example, it has been shown that ERBB-2 is not a major contributor to the development of drug resistance, but when ERBB-2 dimerizes with ERBB-3, this complex is associated with the development of significant drug resistance (Munster et al., 2002) . ERBB-3 has also been shown to be a marker of poor prognosis in a study involving 73 lung cancer patients (Lai et al., 2001 ). This group immunohistochemically evaluated the expression of members of the epidermal growth factor receptor family, and ERBB-3 correlated with enhanced distant metastasis in this patient population. The enhanced expression of ERBB-3 may thus indicate the development of a more malignant phenotype.
MIC1 is a member of the transforming growth factorb superfamily of genes. The MIC1 gene has been designated in other studies as a prostate-derived factor (PDF), placental transforming growth factor-b (PTGFb), placental bone morphogenetic protein (PLAB), growth differentiation factor-15 (GDF-15) and nonsteroidal anti-inflammatory drug-activated gene (NAG-1). MIC1 is a p53-responsive gene expressed specifically at high levels in gastric, prostate and colorectal cancer tissues (reviewed in Lee et al., 2003) . In addition, significantly elevated levels of secreted MIC1 protein were detected in the serum of patients with colorectal, breast and prostate carcinomas (Welsh et al., 2003) . These results suggest that MIC1 may be important in the development or progression of these tumors. The expression of MIC-1 mRNA is increased in response to several signaling molecules in addition to transforming growth factor-b. These include interleukin 1b, tumor necrosis factor a, interleukin 2 and macrophage colonystimulating factor (Bootcov et al., 1997) . MIC1 expression is activated by the phosphatidylinositol-3 kinase/ akt (PI-3 kinase/akt) pathway (Campbell et al., 2001) . The PI-3 kinase/akt pathway is well known for promoting the survival of tumor cells and for being involved in the development of drug resistance to a number of different chemotherapeutic agents (Brognard et al., 2001) . To our knowledge, MIC1 has never been suggested to be involved in resistance to any chemotherapeutic drug.
Both MIC1 and ERBB-3 are involved in the PI-3 kinase/akt signaling pathway (Campbell et al., 2001; Citri et al., 2003) . The ERBB-2-ERBB-3 dimer, which is the most active ERBB dimer, signals through the PI-3 kinase/akt pathway, which promotes cellular survival and antiapoptotic signals (Citri et al., 2003) . The overexpression of two proteins involved in a signaling pathway associated with tumor cell survival and drug resistance suggests that these two proteins may act by way of the PI-3 kinase/akt pathway to promote cisplatin resistance in lung cancer. Further studies may be warranted to evaluate whether the expression of MIC1 and ERBB-3, alone or in combination, influences lung cancer resistance to cisplatin via this pathway.
A frequently discussed issue in the literature related to the study of drug resistance is whether drug resistance represents a truly dynamic cellular process or the establishment of drug resistance is merely a process of selecting cells in the population that already have a drug-resistant phenotype. For example, when a tumor is treated multiple times with the same chemotherapeutic agent, it is conceivable that the tumor cells sensitive to the therapy will undergo apoptosis. Over time, the resistant cells already existent at the initiation of therapy would be expected to make up a greater percentage of the tumor as the sensitive cells are killed; therefore, the tumor would be expected to be more resistant to the chemotherapeutic drug. It is possible that the gene changes observed throughout the 5-week time-course studies using microarray analysis may not represent a truly dynamic cellular process of acquiring cisplatin resistance. Instead, the gene changes observed during the 5-week time-course studies may simply be the result of selecting for a minority of cells in the original cell population, before treatment, that already displayed these gene changes. The results of the 5-week time-course study with NCI-H2170, however, suggest that acquired cisplatin resistance may be a dynamic process. Note that the acquired cisplatin resistance present during the fourth week in this cell line was completely reversed during the fifth week of the study. If indeed the sensitive cells are killed and are replaced by more resistant cells, it would seem very unlikely that during the fifth week these sensitive cells would somehow reappear in the cell population so that the cisplatin-treated cells display no significant resistance to cisplatin.
In general, the results of real-time PCR could confirm approximately most of the gene expression ratios obtained by microarray analysis for selected genes from both the NCI-H226 and NCI-H2170 cell lines. Our ability to confirm gene expression results obtained by microarray analysis using real-time PCR compares favorably with those of other studies (Kudoh et al., 2000; Rajeevan et al., 2001) . The correlation between gene expression and RT-PCR differed slightly between the cell lines. One reason for this discrepancy may be the inadequacy of the housekeeping gene used to normalize the real-time PCR data. GAPDH was used to normalize the real-time PCR data for both cell lines. GAPDH ratios (treated/control) for NCI-H2170 varied by 14.1-fold during the 5-week time-course experiment, whereas the variation between weeks for NCI-H226 was only 4.0-fold. A similar variation in GAPDH expression was also observed during microarray analysis in both cell lines: significant variation in NCI-H2170 and very little variation in NCI-H226. Many investigators suggest using a ribosomal protein for normalizing real-time PCR data; however, it was observed in the present model system that ribosomal protein expression was significantly altered by cisplatin treatment.
Another factor that may explain the lack of perfect correlation between the real-time PCR data and the microarray data for NCI-H2170 is that cDNA synthesis was performed differently for the two methods. Realtime PCR involved cDNA synthesized using random hexamers and total RNA; however, the labeled cDNA used for the microarray experiments was synthesized using gene-specific primers, and the total RNA was first purified so that cDNA synthesis was carried out with mRNA and not total RNA. The advantages and disadvantages of various methods of synthesizing cDNA have previously been considered (Zhang and Byrne, 1999) . In general, gene-specific priming is considered to be a more sensitive method for synthesizing cDNA samples that accurately reflect mRNA transcript levels. In addition, long primers of about 22 base pairs, which were used in the gene-specific primer mix of this study, are more sensitive than random hexamers for synthesizing cDNA pools that best reflect mRNA levels in experimental samples.
In conclusion, we have reported a novel time-course cDNA microarray analysis method that was able to identify unique genes never before associated with cisplatin resistance. Some of these unique genes have been previously associated with cancer progression and may indicate that cancer cells become more malignant as they develop drug resistance. Future studies will examine whether the protein products, and their pathways, of the unique genes identified in this study could serve as useful targets of chemopreventive strategies that may inhibit the cisplatin resistance development process.
Materials and methods
Cell culture
Two squamous cell lung cancer cell lines, NCI-H226 and NCI-H2170, were propagated in folate-free RPMI-1640 (SigmaAldrich; St Louis, MO, USA) supplemented with 10% dialysed fetal bovine serum (Hyclone, Logan, UT, USA), 3 mg/ml sodium bicarbonate, 2 mM L-glutamine, 100 U/ml penicillin G, 100 U/ml streptomycin, 0.25 mg/ml fungizone and 100 ng/ml folate. Both of the cell lines were established from lung cancers diagnosed as nonsmall-cell lung cancer (NSCLC). NCI-H226 was derived from intrapleural metastases of NSCLC. The tissue donors for both cell lines were nonsmokers. The patient from whom tissue for growth of cell line NCH-H226 was obtained did not have radiation therapy or chemotherapy before the cell line was established, and did not receive treatment after the cell line was established (Phelps et al., 1996) . Analogous patient data were not available for cell line NCI-H2170. Previous experiments using an IC 10 dose of cisplatin demonstrated that NCI-H226 readily developed cisplatin resistance, whereas NCI-H2170 did not. NCI-H226 cells were propagated for 5 weeks, and were treated weekly with 2 mM (an IC 10 dose) cisplatin. NCI-H2170 cells were propagated for 5 weeks, and were treated weekly during the first 3 weeks with 1.4 mM (an IC 10 dose) cisplatin, 4.1 mM cisplatin in week 4 and 2.0 mM cisplatin in week 5. Cisplatin was added on day 2 of each week for 16-20 h in both cell culture experiments when the cells were in the log-phase growth.
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT)-based cytotoxicity assay
The level of drug resistance acquired by each cell line was determined by measuring the change in the IC 50 (inhibitory concentration 50: the dose of cisplatin required to inhibit growth of the cell line by 50%) level for cisplatin over the 5-week study. This was accomplished by performing an MTT-based cytotoxicity assay according to a previously published method that has been shown to produce similar results when compared with a clonogenic assay (Plumb et al., 1989) . The MTT-based cytotoxicity assay was performed at the end of weeks 1 and 5 for NCI-H226, whereas it was performed at the end of every week for NCI-H2170.
cDNA microarray analysis
At the end of each week of the 5-week, time-course experiments, cells were harvested and total RNA extracted using the Atlas Pure Total RNA Labeling System Kit according to the manufacturer's instructions (Clontech Labs, Palo Alto, CA, USA). RNA purity was determined by spectrophotometrically measuring the absorbance at 260 and 280 nm. All RNA samples were of the highest purity with 260/280 ratios of 2.0-2.1, and the RNA was determined to be intact by gel electrophoresis.
[ 32 P]cDNA probes were synthesized using the Atlas Pure Total RNA Labeling System Kit and gene-specific primers provided with the Atlas Cancer 1.2 Array (Clontech Labs), according to the manufacturer's instructions. The labeled probes were hybridized overnight to the Atlas Cancer 1.2 Array, which contains 1176 well-characterized genes, according to the manufacturer's instructions. The array was exposed to a phosphorimaging cassette screen and then scanned using a Storm phosphorimager.
Real-time RT-PCR confirmation of microarray results
cDNA synthesis for real-time PCR was performed as follows. Total RNA (2.5 mg), extracted as described above, was added to a 0.5-ml tube and the total volume was brought to 9.0 ml with RNase-free water. Primer cocktail, 2 ml, was added to each tube. The primer cocktail consisted of 200 ng/ml oligo(dT) 15 (stock concentration 500 ng/ml; Promega, Madison, WI, USA) and 50 ng/ml random hexamers (stock concentration 500 ng/ml; Promega). The tubes were heated in a thermal cycler at 681C for 10 min. The following reagents were then added to each tube: 2 ml dNTP solution (10 mM in each dNTP; Promega), 4 ml 5 Â first-strand MMLV buffer (Gibco BRL, Carlsbad, CA, USA), 2 ml DTT (Gibco BRL) and 0.375 ml MMLV reverse transcriptase (200 U/ml; Gibco BRL). The tubes were heated at 421C for 1 h, after which time 50 ml of water was added to each tube and the contents heated at 981C for 5 min to terminate the reaction. Real-time PCR was performed with the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The PCR reaction was performed using 2 ml of the synthesized cDNA, 12.5 ml SYBR Green PCR Master Mix (Applied Biosystems) and primer (Table 4) . Water was added to make a total reaction volume of 25 ml. PCR was performed using universal cycling parameters.
Statistical analysis
Cisplatin resistance All statistical procedures were performed with SigmaStat 2.03, except where noted (SPSS Inc., Chicago, IL, USA). For the cytotoxicity assay, raw data were used to construct a simple, linear regression plot, from which the IC 50 value was obtained. All data were normally distributed and reported as the mean7s.d. One-way ANOVA was then used to compare differences between the means of the various treatment groups. Tukey's test was used for pair-wise comparisons. Statistical significance was set at Po0.05.
Microarray analysis
The raw microarray data were initially processed using Atlas Image 1.5 software (Clontech Labs) and then the data were further processed using Genespringt Version 4.2. If the un-normalized expression values for both the control and the cisplatin-treated cell lines were not at least twofold above the background intensity, the values were excluded from further consideration. For normalization, the 50th percentile of all measurements was used as a positive control for each sample; each measurement for each gene was divided by this synthetic positive control, assuming that this was at least 0.01. Since normalization may generate negative values due to raw signal below background level, ratios of o0.01 were displayed as 0.01. The normalized intensity ratio was determined by dividing the adjusted signal by the adjusted control strength. A ratio of 1.0 is considered as normal expression; any expression value of over one is overexpressed, and all underexpressed data are less than one, but greater than zero. Owing to a limited data set and the likelihood of identifying events unrelated to cisplatin resistance, we sought to identify genes that were statistically similar between the two data sets. We examined genes that changed expression at least twofold in each experiment. We used GeneSpring s to visualize the pattern of gene expression. The temporal response for genes that were selected for real-time PCR was based on plots of gene expression ratios over time for genes that changed at least twofold from weeks 3 to 4 for the NCIH-2170 cell line.
PCR analysis Relative quantitation was used to evaluate the raw data obtained from real-time PCR. A standard curve was developed by using fourfold dilutions of the cDNA sample. This resulted in a simple linear regression plot where the arbitrary values established by the investigator are related to a specific cycle threshold value. The unknowns are then assigned a value based upon the simple linear regression plot. All standards and unknowns were performed in triplicate. The average value of the triplicate readings for each unknown was then divided by the corresponding value for GAPDH to normalize the data. After normalization, the value obtained for the treated unknown was divided by the value obtained for the corresponding untreated sample. The final value obtained was a measure of the fold change in gene expression for the particular gene of interest between the treated sample and the untreated sample. These values were compared with the gene expression data obtained using microarray analysis by the correlation coefficient. For all analyses a P-value of o0.05 was considered to be statistically significant.
